
Oct. 3-5, 2025
The Times Center
242 W 41st St., New York, NY
Join AGA Allied Group, the Association of Black Gastroenterologists and Hepatologists (ABGH), for their second annual NEXUS: Nurturing, Excelling, and Unifying Sisters in Medicine Conference in the heart of NYC from Oct. 3 through 5, ABGH will gather hundreds of Black women in healthcare across all subspecialties and disciplines for connection, collaboration, and celebration. ABGH cannot wait to welcome you for a weekend of growth and community that will leave you fulfilled and at your best when caring for patients who need our help the most.
Learning objectives:
- Identify barriers and solutions to navigate effective career advancement in the context of intersectionality
- Understand how to capitalize on professional resources to advance health equity
- Discuss ways in which racism in medicine weaponizes the concept of professionalism in daily practice and protocols and how to overcome these systemic obstacles
- Develop skills to allow Black women health care professionals to lead in their careers, contribute to research, collaborate professionally, and enrich the pathway to increasing the number of Black women in medicine
- Identify actionable steps for advocacy and activism as a healthcare professional (NEW for 2025)
- Explore disparate cancer outcomes experienced by Black women, and highlight advancements in the field to study this patient population (NEW for 2025)
- Discuss financial planning and security strategies at different career stages (NEW for 2025)
Course directors:
Sophie Balzora, MD
President, Co-founder
Association of Black Gastroenterologists and Hepatologists
Clinical Professor of Medicine
NYU Grossman School of Medicine
Alexandra Guillaume, MD
Assistant Professor of Clinical Medicine
Renaissance School of Medicine at Stony Brook University
Pascale White, MD
Director | Heath Equity in Action in Liver and Digestive Diseases (HEALD)
Icahn School of Medicine at Mount Sinai
See website for full faculty listings.
Pricing:
Registration Deadline: Sept. 19, 2025, at 11:59 p.m.
- Practicing physicians & scientists
$251.28 + $16.60 fee
- Non-MD/DO/scientist professionals
$215.28 + $14.41 fee
- Physicians in training
$143.28 + $10.04 fee
- Medical students and PhD candidates
$71.28 + $5.66 fee
Registration Deadline: Oct. 1, 2025, at 11:59 p.m.
- Practicing physicians & scientists
$349.00 + $22.53 fee
- Non-MD/DO/scientist health care professionals
$299.00 + $19.50 fee
- Physicians in training
$199.00 + $13.42 fee
- Medical students and PhD candidates
$99.00 + $7.34 fee
- Industry partners
$649.00 + $40.76 fee
Commercial support:
This program is supported by Johnson & Johnson, Lilly, Pfizer, Takeda, Ironwood.
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationships with ineligible companies held within the past 24 months. The AGA Institute implements a mechanism to identify and mitigate all conflicts of interest prior to delivering the educational activity to learners.
CME expiration date: Aug. 25, 2026
Disclosures:
Kelly Issokson, MS, RD, LDN, serving as course director, and speaker for this educational activity, disclosed the following relevant financial relationships:
- Consultant: Takeda and Ironwood
- Speaker: Ajinomoto-Cambrooke
Eric Vasiliauskas, MD, serving as course director, and speaker for this educational activity, has no relevant financial relationships with ineligible companies to disclose.
Madison Simons, PsyD, serving as a speaker for this educational activity, has no relevant financial relationships with ineligible companies to disclose.
All relevant financial relationships have been mitigated.